{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:52:25Z","timestamp":1789015945138,"version":"build-2803163510"},"reference-count":61,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We reviewed the literature (January 2010\u2013June 2021) on the effectiveness of debulking strategies before venetoclax initiation in patients with chronic lymphocytic leukemia to reduce tumor burden, downgrade tumor lysis syndrome (TLS) risk, and avoid hospitalization. Low TLS incidence and reduced TLS risk based on tumor burden were reported following debulking in clinical trials. Real\u2010world observational studies reporting debulking regimens recorded no TLS events, and those without debulking strategies had greater TLS incidence. Debulking prior to venetoclax considerably reduces TLS incidence. Further clinical trials and real\u2010world studies may provide additional evidence on effectiveness of debulking in reducing TLS incidence and hospitalization need.<\/jats:p>","DOI":"10.1002\/jha2.427","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T02:43:00Z","timestamp":1649212980000},"page":"492-506","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies"],"prefix":"10.1002","volume":"3","author":[{"given":"Jeffrey P.","family":"Sharman","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Willamette Valley Cancer Institute and Research Center\/US Oncology Research  Eugene Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana M. L.","family":"Biondo","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Boyer","sequence":"additional","affiliation":[{"name":"Roche Products Limited  Welwyn Garden City UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Fischer","sequence":"additional","affiliation":[{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingfeng","family":"Jiang","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon P.","family":"Kater","sequence":"additional","affiliation":[{"name":"Department of Hematology Cancer Center Amsterdam Lymphoma and Myeloma Center Amsterdam Amsterdam University Medical Centers  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Porro Lur\u00e0","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30422-7"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01580"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00948"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30443-5"},{"issue":"1","key":"e_1_2_10_11_1","first-page":"357","article-title":"Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia","author":"Fischer K","year":"2020","journal-title":"Educ Program."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16345"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.09.045"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0581"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218791333"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90037-X"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127408"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-002-0435-3"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1802454"},{"issue":"1","key":"e_1_2_10_20_1","first-page":"299","article-title":"Obinutuzumab and venetoclax in untreated unfit patients with chronic lymphocytic leukemia","volume":"4","author":"Levin M\u2010D","year":"2020","journal-title":"HemaSphere."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-01-896290"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-853564"},{"issue":"1","key":"e_1_2_10_23_1","first-page":"431","article-title":"Initial results of the phase 2 treatment naive cohort in a phase 1b\/2 study of obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia","volume":"130","author":"Rogers KA","year":"2017","journal-title":"Blood."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127506"},{"issue":"1","key":"e_1_2_10_25_1","first-page":"299","article-title":"Phase 3b study to evaluate debulking regimens prior to initiating venetoclax therapy in untreated patients with chronic lymphocytic leukemia","volume":"4","author":"Sharman J","year":"2020","journal-title":"HemaSphere."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(20)30787-4"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30414-5"},{"issue":"2","key":"e_1_2_10_28_1","first-page":"25","article-title":"Bendamustine (B), followed by obinutuzumab (G) and venetoclax (A) in patients with chronic lymphocytic leukemia (CLL): CLL2\u2010BAG trial of the German CLL study group (GCLLSG)","volume":"35","author":"Cramer P","year":"2017","journal-title":"Oncol Res Treat."},{"issue":"11","key":"e_1_2_10_29_1","first-page":"2384","article-title":"Venetoclax plus bendamustine\u2013rituximab or bendamustine\u2013obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440)","volume":"106","author":"Stilgenbauer S","year":"2021","journal-title":"Haematologica."},{"issue":"2","key":"e_1_2_10_30_1","first-page":"27","article-title":"Primary analysis of the fixed\u2010duration cohort from the phase 2 CAPTIVATE study of first\u2010line ibrutinib + venetoclax for chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"5","author":"Allan JN","year":"2021","journal-title":"HemaSphere."},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7501"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.32_2879"},{"issue":"1","key":"e_1_2_10_33_1","first-page":"32","article-title":"First\u2010line ibrutinib (IBR) + venetoclax (VEN) for patients (PTS) with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): Efficacy and safety results from captivate MRD cohort","volume":"4","author":"Siddiqi T","year":"2020","journal-title":"HemaSphere."},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-121424"},{"issue":"1","key":"e_1_2_10_35_1","first-page":"351","article-title":"Ibrutinib lead\u2010in followed by venetoclax in patients with chronic lymphocytic leukemia: Phase 2 captivate early safety and efficacy results","volume":"2","author":"Ghia P","year":"2018","journal-title":"HemaSphere."},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7502"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900574"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-141716"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129230"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00894"},{"issue":"1","key":"e_1_2_10_41_1","first-page":"25","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory CLL: results of the blood wise tap clarity study","volume":"185","author":"Munir TR","year":"2019","journal-title":"Br J Haematol."},{"issue":"1","key":"e_1_2_10_42_1","first-page":"34","article-title":"Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (bloodwise tap clarity study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy","volume":"181","author":"Munir TR","year":"2018","journal-title":"Br J Haematol."},{"issue":"1","key":"e_1_2_10_43_1","first-page":"311","article-title":"The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory CLL shows acceptable safety and promising early indications of efficacy","volume":"102","author":"Mu\u00f1oz\u2010Vicente S","year":"2017","journal-title":"Haematologica."},{"issue":"1","key":"e_1_2_10_44_1","first-page":"35","article-title":"Initial results of a multicenter, investigator\u2010initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab and venetoclax","volume":"4","author":"Soumerai JD","year":"2020","journal-title":"HemaSphere."},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8006"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123404"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138811"},{"issue":"1","key":"e_1_2_10_48_1","article-title":"A phase I study of duvelisib and venetoclax in patients with relapsed or refractory Cll \/Sll","volume":"134","author":"Crombie JL","year":"2019","journal-title":"Blood"},{"key":"e_1_2_10_49_1","unstructured":"Venclyxto: Summary of product characteristics. AbbVie Inc. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/venclyxto\u2010epar\u2010product\u2010information_en.pdf"},{"issue":"2","key":"e_1_2_10_50_1","first-page":"29","article-title":"MRD\u2010guided or fixed 12 cycles of venetoclax consolidation after venetoclax plus obinutuzumab treatment in first\u2010line FCR unfit patients with CLL: Primary endpoint analysis of the HOVON 139\/GIVE trial","volume":"5","author":"Levin M\u2010D","year":"2021","journal-title":"HemaSphere."},{"key":"e_1_2_10_51_1","article-title":"Fixed\u2010duration ibrutinib and venetoclax (I+V) versus chlorambucil plus obinutuzumab (Clb+O) for first\u2010line (1L) chronic lymphocytic leukemia (CLL): Primary analysis of the phase 3 GLOW study","author":"Kater A","year":"2021","journal-title":"HemaSphere."},{"key":"e_1_2_10_52_1","unstructured":"VENCLEXTA (Venetoclax). Abbvie Inc. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208573s026lbl.pdf"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129260"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15802"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1768384"},{"issue":"14","key":"e_1_2_10_56_1","first-page":"4264","article-title":"Tumor lysis, adverse events, and dose adjustments in 297 venetoclax\u2010treated cll patients in routine clinical practice. Clin","volume":"25","author":"Roeker LE","year":"2019","journal-title":"Cancer Res."},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000180"},{"issue":"2","key":"e_1_2_10_58_1","first-page":"292","article-title":"Comparison of venetoclax inpatient and outpatient ramp\u2010up strategies for CLL. UK multicentre restrospective study","volume":"5","author":"Figueroa MR","year":"2021","journal-title":"HemaSphere."},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04419-w"},{"issue":"2","key":"e_1_2_10_60_1","first-page":"291","article-title":"Safety and effectiveness of venetoclax in combination with rituximab in elderly patients with relapsed\/refractory CLL treated under real\u2010life conditions\u2014data from the observational study VERVE","volume":"5","author":"Schwaner I","year":"2021","journal-title":"HemaSphere."},{"issue":"2","key":"e_1_2_10_61_1","first-page":"712","article-title":"A retrospective analysis of patients with chronic lymphocytic leukemia (CLL) treated with venetoclax in the real\u2010life setting in Spain (VENARES)","volume":"5","author":"Ferra C","year":"2021","journal-title":"HemaSphere."},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002593"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.427","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.427","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T06:53:59Z","timestamp":1692860039000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1002\/jha2.427"],"URL":"https:\/\/doi.org\/10.1002\/jha2.427","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]},"assertion":[{"value":"2021-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}